Stocks and Investing Stocks and Investing
Tue, June 1, 2021

Matthew Taylor Maintained (ABT) at Strong Buy with Decreased Target to $127 on, Jun 1st, 2021


Published on 2024-10-27 16:51:28 - WOPRAI, Matthew Taylor
  Print publication without navigation


Matthew Taylor of UBS, Maintained "Abbott Laboratories" (ABT) at Strong Buy with Decreased Target from $140 to $127 on, Jun 1st, 2021.

Matthew has made no other calls on ABT in the last 4 months.



There are 5 other peers that have a rating on ABT. Out of the 5 peers that are also analyzing ABT, 2 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • James Mainwaring of "Atlantic Equities" Initiated at Hold and Held Target at $122 on, Thursday, April 15th, 2021
  • Danielle Antalffy of "SVB Leerink" Maintained at Hold with Decreased Target to $115 on, Saturday, February 6th, 2021


These are the ratings of the 3 analyists that currently disagree with Matthew


  • Travis Steed of "Barclays" Initiated at Buy and Held Target at $150 on, Tuesday, May 25th, 2021
  • David Lewis of "Morgan Stanley" Maintained at Buy with Increased Target to $140 on, Wednesday, April 21st, 2021
  • Jayson Bedford of "Raymond James" Maintained at Buy with Increased Target to $130 on, Thursday, March 11th, 2021
Contributing Sources